1. Home
  2. SPRO vs AIFC Comparison

SPRO vs AIFC Comparison

Compare SPRO & AIFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

71.6M

Sector

Health Care

ML Signal

HOLD

Logo AI Financial Corporation Common Stock

AIFC

AI Financial Corporation Common Stock

N/A

Current Price

$0.60

Market Cap

73.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
AIFC
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
71.6M
73.3M
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
SPRO
AIFC
Price
$1.21
$0.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
607.0K
923.4K
Earning Date
05-13-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
$12,532,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.08
$0.36
52 Week High
$3.08
$0.72

Technical Indicators

Market Signals
Indicator
SPRO
AIFC
Relative Strength Index (RSI) 34.07 60.64
Support Level $1.18 $0.52
Resistance Level $1.29 $0.63
Average True Range (ATR) 0.05 0.06
MACD 0.03 0.02
Stochastic Oscillator 16.00 63.10

Price Performance

Historical Comparison
SPRO
AIFC

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About AIFC AI Financial Corporation Common Stock

AI Financial Corp is a payment infrastructure company. The company provides payment infrastructure services focused on payment processing and financial transaction technologies. Its capabilities include payment processing, security features, tokenization, and AI-based commerce solutions. It also provides infrastructure for crypto and decentralized finance (DeFi) payment processing and is developing additional capabilities for automated and programmable payment systems.

Share on Social Networks: